0001672619 2026-06-12 2026-06-12 0001672619 1 2026-06-12 2026-06-12 0001672619 2 2026-06-12 2026-06-12 iso4217:USD pure shares S-3 424B5 EX-FILING FEES 333-289582 0001672619 Enliven Therapeutics, Inc. N/A N/A S-3 Enliven Therapeutics, Inc. false Equity Common Stock, par value $0.001 per share true 12266667 37.50 460000012.50 0.0001381 63526.01 false Equity Pre-Funded Warrants to purchase shares of Common Stock, par value $0.001 per share true 1733333 37.50 64999987.50 0.0001381 8976.50 525000000.00 72502.51 0.00 0.00 72502.51 The registration fee is calculated and being paid pursuant to Rule 457(r) of the Securities Act of 1933, as amended (the "Securities Act"). The fee payable in connection with the offering pursuant to this prospectus supplement is being paid herewith in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant's Registration Statement on Form S-3ASR (Registration No. 333-289582). Includes 1,733,333 shares of common stock that are issuable upon the exercise of pre-funded warrants referenced below. This also includes 1,600,000 shares of common stock issuable upon exercise of the underwriters' option to purchase additional shares. Pursuant to Rule 416 under the Securities Act, the pre-funded warrants to purchase common stock being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of share splits, share dividends or similar transactions. The registration fee is calculated in accordance with Rule 457(r) under the Securities Act. Represents the sum of the pre-funded warrants sales price of $37.499 per pre-funded warrant and the exercise price of $0.001 per share of common stock issuable pursuant to the pre-funded warrants. Pursuant to Rule 457(g), the entire fee is allocated to the common stock underlying the pre-funded warrants. 525000000.00 true